SpeeDx Pty Ltd - Company Research Report
Company Overview
Company Name: SpeeDx Pty Ltd
Mission: To deliver innovative clinical diagnostics to improve patient outcomes.
Founded: 2009
Founders: No information is available
Key People:
- Chairman of the Board: Jonathan O. Clark
- Non-Executive Directors:
- Bianca Ogden, MBio, PhD
- Lily Li, PhD
- Vicki DiFrancesco
- Ingo Chakravarty
- Executive Team:
- Chief Executive Officer (CEO): Colin Denver
- Chief Technology Officer (CTO): Elisa Mokany, PhD
- Chief Scientific Officer (CSO): Alison Todd, AM, FTSE, PhD
Headquarters:
- Australia: Suite 102, National Innovation Centre, 4 Cornwallis Street, Eveleigh, NSW 2015, Australia
- Europe: Acre House, 11/15 William Road, London, NW1 3ER, United Kingdom
- USA: 1400 Barbara Jordan Boulevard, Austin, TX 78723, United States
Number of Employees: 51-200
Revenue: No information is available
Known For: Specializes in molecular diagnostic solutions that provide comprehensive information for improved patient management. Focus on multiplex diagnostics for sexually transmitted infections (STI), antibiotic resistance markers, and respiratory diseases.
Products
Diagnostic Tests
1. ResistancePlus® GC
- Description: Single well qPCR test detecting Neisseria gonorrhoeae and markers linked to ciprofloxacin susceptibility.
- Key Features: Detects organism and antibiotic susceptibility markers.
2. ResistancePlus® MG
- Description: Single well qPCR test detecting Mycoplasma genitalium and markers linked to macrolide resistance.
- Key Features: Detects organism and antibiotic resistance markers.
3. ResistancePlus® MG FleXible
- Description: Cartridge-based test detecting M. genitalium and macrolide resistance markers.
- Key Features: For use in Cepheid GeneXpert® systems.
4. PlexPCR® VHS
- Description: Single well qPCR test detecting and differentiating HSV-1, HSV-2, VZV & Treponema pallidum (Syphilis).
- Key Features: Differentiates between multiple herpes and syphilis lesions.
5. PlexPCR® HSV-1&2, VZV
- Description: Single well qPCR test detecting and differentiating HSV-1, HSV-2, and VZV.
- Key Features: High specificity and sensitivity.
6. PlexPCR® Flu/RSV/SARS-CoV-2
- Description: Detects Influenza (A and B), Respiratory Syncytial Virus, and SARS-CoV-2 virus in a single-well multiplex qPCR test.
- Key Features: Efficient and robust detection of key respiratory viruses.
7. PlexPCR® SARS-CoV-2
- Description: Single well qPCR test detecting COVID-19 causing coronavirus, SARS-CoV-2.
- Key Features: Targeting highly conserved regions to ensure robust detection.
8. PlexPCR® RespiVirus
- Description: 2 well qPCR test detecting and differentiating 11 respiratory viruses.
- Key Features: Comprehensive respiratory virus detection.
9. RespiV PlexPlus®
- Description: Single well reaction detecting 14 respiratory targets.
- Key Features: High throughput and high multiplexing efficiency.
10. EntericPlex
- Description: Suite of gastroenteritis panels detecting common enteric pathogens.
- Key Features: Single-well assays focused on parasitic or bacterial gastroenteric pathogens.
11. PlexMonkeypox
- Description: No detailed information available.
12. Flu/RSV/SARS-CoV-2
- Description: No detailed information available.
13. DermatoPlex
- Description: No detailed information available.
14. CT/GC/TV/MGPlex
- Description: Simultaneously detects Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium.
- Key Features: Streamlined STI research workflow.
15. PlexPrime® GC+gyrA
- Description: No detailed information available.
16. STIPlex MG+23S
- Description: No detailed information available.
17. PlexPrime® HSV, VZV, TP
- Description: No detailed information available.
Automation Solutions
1. PlexPrep® Automation
- Description: Robotic pipetting for sample extraction preparation, master mix, and qPCR reaction set-up.
- Key Features: Minimizes hands-on time, improves laboratory productivity.
Accessories & Controls
1. ResistancePlus® GC Control
2. ResistancePlus® MG Positive Control
3. ResistancePlus® MG S2A Positive Control
4. PlexPCR® RespiVirus Positive Control
5. PlexPCR® Colour Compensation
6. Positive Control Flu/RSV/SARS
Recent Developments
Recent Achievements
1. SpeeDx Compact Respiratory Multiplex – now Class D IVDR Certified
- Date: September 6, 2024
- Details: SpeeDx received IVDR Class D certification for its PlexPCR® Flu/RSV/SARS-CoV-2 test.
2. Launch of Next Generation PCR Multiplexing Technology
- Date: April 9, 2024
- Details: Launch of RespiV PlexPlus®, detecting 14 respiratory viral targets in a single well.
3. Expansion in Enteric Testing
- Date: December 8, 2023
- Details: Released EntericPlex RUO assays detecting gastroenteric pathogens.
4. Compact Respiratory Multiplex and Seasonal Testing
- Date: September 1, 2023
- Details: Released Compact Respiratory Multiplex to improve testing for the UK winter.
5. Expansion of Research Offering
- Date: July 12, 2023
- Details: Released new RUO products to expand research offerings.
Partnerships
- Northpond Ventures: Northpond Ventures is a significant partner and advisor for SpeeDx, providing operational and strategic support.
New Features and Product Improvements
- PlexPlus® Technology: Introduced to double the standard target output without specialized equipment, enhancing multiplex qPCR performance.
Additional Information
Locations and Contact Information:
- Australia: Suite 102, National Innovation Centre, 4 Cornwallis Street, Eveleigh, NSW 2015 Australia, +61 (0)2 9209 4170, sales@speedx.com.au
- Europe: Acre House, 11/15 William Road, London, NW1 3ER, United Kingdom, +44 (0)330 445 0036, sales.uk@speedx.com.au
- USA: 1400 Barbara Jordan Boulevard, Austin, TX 78723, United States, +1 512 200 6918, sales.us@speedx.com.au
Social Media
- YouTube
Note: The report is strictly based on the information available in the provided data and fields with missing information are noted as "No information is available".
